UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 20, 2006
SOMAXON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
| | | | | |
| Delaware | | 000-51665 | | 20-0161599 |
| (State or Other Jurisdiction | | (Commission | | (IRS Employer |
| of Incorporation) | | File Number) | | Identification No.) |
| | | | | |
| 3721 Valley Centre Drive, Suite 500, San Diego, California | | | | 92130 |
| (Address of Principal Executive Offices) | | | | (Zip Code) |
Registrant’s telephone number, including area code:(858) 480-0400
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01. Other Events
On November 20, 2006, Somaxon Pharmaceuticals, Inc. issued a press release announcing the results from the third of four Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin hydrochloride) for the treatment of insomnia. The trial was a randomized, double-blind, placebo-controlled, multi-center, parallel group outpatient trial designed to assess the efficacy and safety of 6mg of SILENOR™ in elderly patients with primary sleep maintenance insomnia. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
| | | | | |
| | | Exhibit No. | | Description |
| | | 99.1 | | Press Release, dated November 20, 2006 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | |
| | | SOMAXON PHARMACEUTICALS, INC. |
| | | | | | | |
| Date: November 20, 2006 | | | | | | |
| | | | | | | |
| | | By: | | /s/ Kenneth M. Cohen | | |
| | | | | | | |
| | | Name: | | Kenneth M. Cohen | | |
| | | Title: | | President and Chief Executive Officer | | |
EXHIBIT INDEX
| | | | | |
| | | Exhibit No. | | Description |
| | | 99.1 | | Press Release, dated November 20, 2006 |
